TORRENT PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
TORRENT PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 Audited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,732 Cr | ₹2,660 Cr | ₹2,591 Cr | ₹2,491 Cr | ₹2,491 Cr | ₹2,291 Cr | ₹2,347 Cr | ₹2,131 Cr |
Expenses | ₹1,863 Cr | ₹1,835 Cr | ₹1,800 Cr | ₹1,764 Cr | ₹1,767 Cr | ₹1,612 Cr | ₹1,635 Cr | ₹1,570 Cr |
Operating Income | ₹869 Cr | ₹825 Cr | ₹791 Cr | ₹727 Cr | ₹724 Cr | ₹679 Cr | ₹712 Cr | ₹561 Cr |
Other Income | ₹-33 Cr | ₹26 Cr | ₹34 Cr | ₹9 Cr | ₹-10 Cr | ₹16 Cr | ₹30 Cr | ₹56 Cr |
Interest | ₹80 Cr | ₹91 Cr | ₹103 Cr | ₹107 Cr | ₹102 Cr | ₹69 Cr | ₹55 Cr | ₹57 Cr |
Depreciation | ₹213 Cr | ₹201 Cr | ₹191 Cr | ₹196 Cr | ₹193 Cr | ₹163 Cr | ₹155 Cr | ₹162 Cr |
Profit Before Tax | ₹631 Cr | ₹559 Cr | ₹531 Cr | ₹433 Cr | ₹419 Cr | ₹463 Cr | ₹532 Cr | ₹-87 Cr |
Profit After Tax | ₹443 Cr | ₹386 Cr | ₹378 Cr | ₹287 Cr | ₹292 Cr | ₹312 Cr | ₹354 Cr | ₹-118 Cr |
EPS | ₹13.09 | ₹11.40 | ₹11.17 | ₹8.48 | ₹8.63 | ₹9.22 | ₹10.46 | ₹-3.49 |
Industry Peers & Returns | 1W | 1M | 1Y |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
MANKIND PHARMA | 1.3% | 7% | NA |
LUPIN | 0.6% | 0.5% | 127.2% |
AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
TORRENT PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 2.71 % |
Y-o-Y | 9.67 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹2,732 Cr | 2.71 | |
Sep2023 | ₹2,660 Cr | 2.66 | |
Jun2023 | ₹2,591 Cr | 4.01 | |
Mar2023 | ₹2,491 Cr | 0.00 | |
Dec2022 | ₹2,491 Cr | 8.73 | |
Sep2022 | ₹2,291 Cr | -2.39 | |
Jun2022 | ₹2,347 Cr | 10.14 | |
Mar2022 | ₹2,131 Cr | - |
TORRENT PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 5.33 % |
Y-o-Y | 20.03 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹869 Cr | 5.33 | |
Sep2023 | ₹825 Cr | 4.30 | |
Jun2023 | ₹791 Cr | 8.80 | |
Mar2023 | ₹727 Cr | 0.41 | |
Dec2022 | ₹724 Cr | 6.63 | |
Sep2022 | ₹679 Cr | -4.63 | |
Jun2022 | ₹712 Cr | 26.92 | |
Mar2022 | ₹561 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 2.55 % |
Y-o-Y | 9.46 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 31.81% | 2.55 | |
Sep2023 | 31.02% | 1.60 | |
Jun2023 | 30.53% | 4.59 | |
Mar2023 | 29.19% | 0.45 | |
Dec2022 | 29.06% | -1.96 | |
Sep2022 | 29.64% | -2.31 | |
Jun2022 | 30.34% | 15.23 | |
Mar2022 | 26.33% | - |
TORRENT PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 14.77 % |
Y-o-Y | 51.71 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹443 Cr | 14.77 | |
Sep2023 | ₹386 Cr | 2.12 | |
Jun2023 | ₹378 Cr | 31.71 | |
Mar2023 | ₹287 Cr | -1.71 | |
Dec2022 | ₹292 Cr | -6.41 | |
Sep2022 | ₹312 Cr | -11.86 | |
Jun2022 | ₹354 Cr | Positive | |
Mar2022 | ₹-118 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 11.78 % |
Y-o-Y | 38.40 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 16.22 % | 11.78 | |
Sep2023 | 14.51 % | -0.55 | |
Jun2023 | 14.59 % | 26.65 | |
Mar2023 | 11.52 % | -1.71 | |
Dec2022 | 11.72 % | -13.95 | |
Sep2022 | 13.62 % | -9.68 | |
Jun2022 | 15.08 % | Positive | |
Mar2022 | -5.54 % | - |
TORRENT PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 14.82 % |
Y-o-Y | 51.68 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹13.09 | 14.82 | |
Sep2023 | ₹11.4 | 2.06 | |
Jun2023 | ₹11.17 | 31.72 | |
Mar2023 | ₹8.48 | -1.74 | |
Dec2022 | ₹8.63 | -6.40 | |
Sep2022 | ₹9.22 | -11.85 | |
Jun2022 | ₹10.46 | Positive | |
Mar2022 | ₹-3.49 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD